HPRA - Information Update on Medicines from HPRA
 

 

The 99th edition of the HPRA Drug Safety Newsletter includes information on the following medicines:

  • Erythromycin – Updated warnings regarding cardiovascular risks and infantile hypertrophic pyloric stenosis
  • Vascular Endothelial Growth Factor (VEGF) pathway inhibitors – Risk of aneurysm and artery dissection
  • Implanon NXT (etonogestrel implant) – Updated insertion and removal instructions due to risk of neurovascular injury and implant migration
  • Insulin-containing medicines – Risk of cutaneous amyloidosis and potential for associated changes in glycaemic control
  • Leuprorelin-containing depot medicines – Risk of lack of efficacy due to incorrect reconstitution and administration
  • Xeljanz ▼(tofacitinib) – Updated recommendations due to increased risk of venous thromboembolism and serious and fatal infections
  • Risk of respiratory depression and sedation associated with Epaclob 1mg/ml and 2mg/ml oral suspension (clobazam)

For further details please visit the HPRA website.

Rate: 12345 (3) | Facebook Twitter LinkedIn Digg Yammer
In this issue
Reflection on my time on the NMBI Registration Committee
MyNMBI is LIVE!
Annual Renewal for 2021 – NOTICES TO CIRCULATE LATE NOVEMBER
Are there Aspiring Nurses and Midwives at Home? Check out Higher Options 2020 - 4 and 5 November
Board Elections for 2020 - Three Candidates Elected
HPRA - Information Update on Medicines from HPRA
Monthly Spotlight - Muireann Ní Riain, CNS Acute Hospital Liaison Nurse
Update DetailsSend to a friendArchive